IVA

Inventiva S.A.

Price Chart

Latest Quote

$3.50

+0.04 (+1.16%)

Current Price

Previous Close	$3.46
Open	$3.48
Day High	$3.53
Day Low	$3.41
Volume	2,121,069

Fetched: 2026-06-25T23:13:58

Stock Information

Note: Financial values converted from EUR to USD

Shares Outstanding	236.22M
Total Debt	$262.52M
Cash Equivalents	$113.52M
Revenue	$7.69M
Net Income	$-402.66M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$826.77M
EPS (TTM)	$-2.17
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$849.72M
Sales	$7.69M
Income	$-402.66M
Book/sh	$-0.17
Cash/sh	$0.42
Employees	69

Financial Ratios

Quick Ratio	1.41
Current Ratio	3.16

Returns & Margins

ROA	-45.08%
Gross Margin	99.68%
Operating Margin	-6710.69%

Ownership

Institutional Ownership	25.64%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-3.98
P/S	122.29
P/B	-20.29

Analyst Data

Recommendation	strong_buy
Target Price	$15.13

Technical Indicators

SMA20	$3.96
SMA50	$4.77
SMA200	$5.23
RSI	26.45
ATR	0.1929

Shares Float	154.23M
Short Float	0.35%
Short Ratio	2.99
Volatility	0.88
Rel Volume	1.91

Performance History

Week	-0.85%
Month	-32.17%
Quarter	-41.86%
6 Months	-20.99%
YTD	-26.47%
Year	+11.82%
3 Years	-26.47%
5 Years	-75.95%
10 Years	-73.92%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-25	$3.50	2,121,069
2026-06-24	$3.46	1,094,400
2026-06-23	$3.71	1,527,400
2026-06-22	$3.51	862,500
2026-06-18	$3.57	3,549,800
2026-06-17	$3.53	1,033,900
2026-06-16	$3.58	474,800
2026-06-15	$3.76	350,700
2026-06-12	$3.85	1,009,400
2026-06-11	$3.80	831,700
2026-06-10	$3.78	645,100
2026-06-09	$3.97	973,000
2026-06-08	$3.91	314,000
2026-06-05	$4.03	1,083,100
2026-06-04	$4.23	1,919,200
2026-06-03	$4.04	1,251,000
2026-06-02	$4.09	2,606,200
2026-06-01	$4.77	358,200
2026-05-29	$4.93	76,200
2026-05-28	$5.23	135,900
2026-05-27	$5.22	151,400
2026-05-26	$5.16	127,300

About Inventiva S.A.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

📰 Latest News

Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround

Zacks • 2026-06-11T13:35:02Z

Assessing Inventiva (ENXTPA:IVA) Valuation As Losses Deepen And MASH Trial Progresses

Simply Wall St. • 2026-05-21T06:11:30Z

How The Inventiva (ENXTPA:IVA) Story Is Shifting As Analyst Views Grow More Divided

Simply Wall St. • 2026-05-20T00:21:23Z

Inventiva Builds Up Leadership Team Ahead of Potential Commercialization

Exec Edge • 2026-04-22T22:03:19Z

How The Inventiva (ENXTPA:IVA) Story Is Shifting With Lanifibranor And Analyst Revisions

Simply Wall St. • 2026-04-07T04:32:40Z

Inventiva SA (IVA) (Q4 2025) Earnings Call Highlights: Strategic Milestones and Financial ...

GuruFocus.com • 2026-04-02T01:01:02Z

Inventiva Q4 Earnings Call Highlights

MarketBeat • 2026-03-31T14:10:34Z

Assessing Inventiva (ENXTPA:IVA) Valuation After A Strong 12‑Month Rebound In Shareholder Returns

Simply Wall St. • 2026-02-28T23:13:56Z

Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect?

Zacks • 2026-02-27T14:55:03Z

Inventiva CEO: Phase 3 Lanifibranor MASH Trial Fully Enrolled, Top-Line Data Due in H2

MarketBeat • 2026-02-14T05:02:10Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$5,098,953	$10,461,783	$19,878,298	$13,852,365
Operating Revenue	$5,098,953	$10,461,783	$19,878,298	$13,852,365
Expenses
Interest Expense	$38,175,613	$13,851,228	$5,889,445	$804,140
Total Expenses	$156,239,759	$117,364,646	$136,649,222	$78,521,381
Other Income Expense	$-216,733,387	$-89,675,839	$-3,321,201	$3,329,163
Net Non Operating Interest Income Expense	$-34,893,084	$-12,589,854	$-4,814,604	$-414,013
Total Other Finance Cost	$67,106	$38,672	$52,320	$53,458
Interest Expense Non Operating	$38,175,613	$13,851,228	$5,889,445	$804,140
Operating Expense	$156,239,759	$117,364,646	$136,649,222	$78,521,381
Other Operating Expenses	$-4,347,134	$-6,239,763	$-6,467,243	$-7,881,028
Selling And Marketing Expense	$5,506,142	$1,917,652	$1,996,133	$2,689,945
General And Administrative Expense	$55,790,490	$17,530,709	$15,755,232	$14,684,940
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-402,795,711	$-209,522,287	$-125,598,267	$-61,731,117
Net Interest Income	$-34,893,084	$-12,589,854	$-4,814,604	$-414,013
Interest Income	$3,349,636	$1,300,045	$1,127,161	$443,585
Normalized Income	$-240,544,238	$-142,532,412	$-124,826,259	$-65,058,283
Net Income From Continuing And Discontinued Operation	$-402,795,711	$-209,522,287	$-125,598,267	$-61,731,117
Total Operating Income As Reported	$-160,387,848	$-110,962,235	$-116,820,970	$-64,956,777
Net Income Common Stockholders	$-402,795,711	$-209,522,287	$-125,598,267	$-61,731,117
Net Income	$-402,795,711	$-209,522,287	$-125,598,267	$-61,731,117
Net Income Including Noncontrolling Interests	$-402,792,299	$-209,524,561	$-125,597,130	$-61,731,117
Net Income Continuous Operations	$-402,792,299	$-209,524,561	$-125,597,130	$-61,731,117
Pretax Income	$-402,767,276	$-209,168,556	$-124,906,730	$-61,753,865
Special Income Charges	$-9,245,905	$-4,059,372	$-50,045	$-147,862
Earnings From Equity Interest	$-398,089	$-356,005	$-2,291,856	$0
Interest Income Non Operating	$3,349,636	$1,300,045	$1,127,161	$443,585
Operating Income	$-151,140,805	$-106,902,863	$-116,770,925	$-64,669,015
Depreciation Amortization Depletion Income Statement	$287,762	$789,354	$237,716	$250,227
Depreciation And Amortization In Income Statement	$287,762	$789,354	$237,716	$250,227
Per Share
Diluted EPS	$-2.16	$-3.50	$-2.76	$-1.49
Basic EPS	$-2.16	$-3.50	$-2.76	$-1.49
Other
Tax Effect Of Unusual Items	$-54,083,825	$-22,329,958	$-257,336	$1,997
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-144,590,533	$-100,085,302	$-115,031,844	$-62,347,587
Total Unusual Items	$-216,335,298	$-89,319,834	$-1,029,345	$3,329,163
Total Unusual Items Excluding Goodwill	$-216,335,298	$-89,319,834	$-1,029,345	$3,329,163
Reconciled Depreciation	$3,665,832	$5,912,193	$2,956,096	$1,931,301
EBITDA (Bullshit earnings)	$-360,925,831	$-189,405,135	$-116,061,189	$-59,018,424
EBIT	$-364,591,663	$-195,317,328	$-119,017,285	$-60,949,725
Diluted Average Shares	$211,997,743	$67,992,151	$51,583,027	$47,144,826
Basic Average Shares	$211,997,743	$67,992,151	$51,583,027	$47,144,826
Diluted NI Availto Com Stockholders	$-402,795,711	$-209,522,287	$-125,598,267	$-61,731,117
Tax Provision	$25,023	$356,005	$690,400	$-22,748
Gain On Sale Of Ppe	$324,158	$170,610	$0	$-10,237
Restructuring And Mergern Acquisition	$9,570,063	$4,229,982	$50,045	$137,625
Gain On Sale Of Security	$-207,089,393	$-85,260,461	$-979,299	$3,477,024
Research And Development	$99,002,499	$103,366,694	$125,127,385	$68,777,295
Selling General And Administration	$61,296,631	$19,448,362	$17,751,364	$17,374,886
Other Gand A	$12,372,611	$10,660,828	$10,105,778	$9,927,206
Insurance And Claims	$1,761,829	$0	$0	-
Salaries And Wages	$41,656,050	$6,869,882	$5,649,454	$4,757,734
Write Off	-	$423,112	$0	$0
Impairment Of Capital Assets	-	$2,032,530	$0	$0
Other Taxes	-	-	$0	$0
Provision For Doubtful Accounts	-	-	$0	$0

Fetched: 2026-06-25

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-32,648,998	$-121,353,500	$-37,048,452	$51,078,251
Total Assets	$283,793,213	$135,312,780	$79,118,514	$131,942,671
Total Non Current Assets	$5,737,033	$8,480,437	$24,310,736	$10,944,040
Non Current Prepaid Assets	$1,321,656	$1,190,855	$11,436,533	$1,823,248
Non Current Deferred Assets	$217,243	$246,815	$255,914	$0
Non Current Deferred Taxes Assets	$217,243	$246,815	$255,914	$0
Goodwill And Other Intangible Assets	$208,144	$54,595	$616,469	$646,042
Other Intangible Assets	$208,144	$54,595	$616,469	$646,042
Current Assets	$278,058,454	$126,832,344	$54,810,053	$121,000,906
Other Current Assets	$598,271	$396,952	$478,844	$320,746
Prepaid Assets	$4,494,995	$2,777,525	$5,295,723	$9,782,757
Inventory	$0	$0	$474,295	$424,249
Receivables	$10,374,204	$13,827,343	$17,865,104	$10,626,706
Other Receivables	$1,906,278	$1,853,958	$1,685,623	$317,334
Taxes Receivable	$6,174,932	$11,369,426	$11,849,408	$10,309,372
Accounts Receivable	$2,292,994	$603,958	$4,330,073	$0
Cash Cash Equivalents And Short Term Investments	$262,590,984	$109,830,524	$30,696,086	$99,846,448
Cash And Cash Equivalents	$112,957,230	$109,830,524	$30,616,469	$98,654,456
Cash Equivalents	$93,980,889	$80,362,827	$20,396,951	$19,106,005
Cash Financial	$18,976,342	$29,467,697	$10,219,517	$79,548,451
Investmentin Financial Assets	-	-	$10,236,578	$796,178
Non Current Accounts Receivable	-	-	-	$73,931
Hedging Assets Current	-	-	-	$0
Other Non Current Assets	-	-	-	-
Debt
Total Debt	$68,083,483	$61,793,674	$42,639,899	$39,257,278
Long Term Debt And Capital Lease Obligation	$31,336,441	$55,119,425	$36,602,592	$32,602,365
Long Term Debt	$30,500,454	$52,691,081	$31,749,317	$28,925,158
Current Debt And Capital Lease Obligation	$36,747,042	$6,674,249	$6,037,306	$6,654,913
Current Debt	$34,431,300	$3,808,007	$3,423,567	$5,202,457
Other Current Borrowings	$34,431,300	$3,808,007	$3,423,567	$5,202,457
Net Debt	-	-	$4,556,415	-
Liabilities
Total Liabilities Net Minority Interest	$316,234,067	$256,611,685	$115,550,497	$80,218,378
Total Non Current Liabilities Net Minority Interest	$228,224,515	$119,292,535	$58,500,908	$45,299,134
Other Non Current Liabilities	$60,097,814	$34,391,491	$8,370,109	$-2,275
Derivative Product Liabilities	$135,788,212	$27,655,823	$11,675,386	$11,232,939
Non Current Deferred Liabilities	$143,312	$121,702	$79,618	$62,557
Current Liabilities	$88,009,551	$137,319,150	$57,049,589	$34,919,244
Other Current Liabilities	$1,137	$83,486,121	-	$-1,137
Current Deferred Liabilities	$0	$0	$6,824	$6,824
Payables And Accrued Expenses	$50,043,220	$47,158,779	$51,005,458	$28,258,643
Payables	$37,828,707	$45,178,570	$49,253,866	$26,734,531
Other Payable	$6,223,840	$3,338,262	$2,151,956	$2,136,033
Total Tax Payable	$2,013,194	$4,463,148	$4,245,905	$2,579,618
Accounts Payable	$29,591,673	$37,377,160	$42,856,004	$22,018,880
Current Deferred Taxes Liabilities	-	-	$0	$0
Equity
Common Stock Equity	$-32,440,854	$-121,298,904	$-36,431,983	$51,724,293
Total Equity Gross Minority Interest	$-32,440,854	$-121,298,904	$-36,431,983	$51,724,293
Stockholders Equity	$-32,440,854	$-121,298,904	$-36,431,983	$51,724,293
Gains Losses Not Affecting Retained Earnings	$-232,650,129	$-196,259,093	$-141,023,654	$-84,800,953
Other Equity Adjustments	$-233,373,514	$-196,941,532	$-141,701,543	$-84,492,718
Retained Earnings	$-402,795,711	$-209,522,287	$-125,598,267	$-61,731,117
Long Term Equity Investment	$599,409	$1,295,496	$1,620,792	$0
Other
Treasury Shares Number	$67,733	$137,081	$120,695	-
Ordinary Shares Number	$219,719,542	$108,806,174	$59,276,394	$47,923,303
Share Issued	$219,787,275	$108,943,255	$59,397,089	$47,923,303
Tangible Book Value	$-32,648,998	$-121,353,500	$-37,048,452	$51,078,251
Invested Capital	$32,490,900	$-64,799,816	$-1,259,099	$85,851,908
Working Capital	$190,048,902	$-10,486,806	$-2,239,536	$86,081,663
Capital Lease Obligations	$3,151,729	$5,294,586	$7,467,015	$5,129,663
Total Capitalization	$-1,940,400	$-68,607,823	$-4,682,666	$80,649,452
Foreign Currency Translation Adjustments	$723,385	$682,439	$677,889	$-308,235
Additional Paid In Capital	$600,807,534	$283,393,986	$229,597,354	$197,777,519
Capital Stock	$2,197,452	$1,088,490	$592,584	$478,844
Common Stock	$2,197,452	$1,088,490	$592,584	$478,844
Employee Benefits	$858,735	$2,004,095	$1,773,203	$1,403,549
Non Current Pension And Other Postretirement Benefit Plans	$858,735	$2,004,095	$1,773,203	$1,403,549
Non Current Deferred Revenue	$143,312	$121,702	$79,618	$62,557
Long Term Capital Lease Obligation	$835,987	$2,428,344	$4,853,276	$3,677,206
Current Deferred Revenue	$0	$0	$6,824	$6,824
Current Capital Lease Obligation	$2,315,742	$2,866,242	$2,613,740	$1,452,457
Current Provisions	$1,218,153	-	-	-
Current Accrued Expenses	$12,214,513	$1,980,209	$1,751,592	$1,524,113
Investments And Advances	$599,409	$1,295,496	$1,620,792	$0
Net PPE	$3,390,582	$5,692,675	$10,381,028	$8,400,819
Accumulated Depreciation	$-19,290,263	$-17,280,482	$-12,184,940	$-9,731,574
Gross PPE	$22,680,846	$22,973,157	$22,565,968	$18,132,393
Construction In Progress	$0	$22,748	$130,801	$73,931
Other Properties	$13,106,233	$12,189,490	$11,918,789	$7,709,281
Machinery Furniture Equipment	$5,433,348	$6,618,517	$6,373,976	$6,206,779
Buildings And Improvements	$3,945,632	$3,946,770	$3,946,770	$3,946,770
Land And Improvements	$195,632	$195,632	$195,632	$195,632
Properties	$0	$0	$0	$0
Other Short Term Investments	$149,633,753	$0	$79,618	$1,191,993
Available For Sale Securities	-	-	$10,236,578	$796,178
Other Inventories	-	-	$474,295	$424,249

Fetched: 2026-06-25

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-119,575,747	$-98,113,054	$-93,441,762	$-51,739,079
Operating Activities
Operating Cash Flow	$-119,294,810	$-97,734,301	$-92,827,568	$-51,100,999
Cash Flow From Continuing Operating Activities	$-119,297,085	$-97,733,164	$-92,827,568	$-51,099,862
Operating Gains Losses	$1,974,522	$-589,172	$2,629,663	$390,127
Investing Activities
Capital Expenditure	$-280,937	$-378,753	$-614,195	$-638,080
Investing Cash Flow	$-151,485,437	$9,946,542	$-8,793,221	$10,086,442
Cash Flow From Continuing Investing Activities	$-151,484,299	$9,946,542	$-8,793,221	$10,085,305
Net Other Investing Changes	$-1,137	-	-	$1,137
Financing Activities
Issuance Of Capital Stock	$234,805,498	$65,216,104	$34,791,855	$10,039,809
Financing Cash Flow	$274,438,117	$165,595,991	$33,076,660	$42,388,534
Cash Flow From Continuing Financing Activities	$274,436,980	$165,595,991	$33,076,660	$42,388,534
Net Other Financing Charges	$-19,487,033	$11,483,166	$2,944,722	$34,359,644
Cash Dividends Paid	$0	$0	$0	-
Net Common Stock Issuance	$234,805,498	$65,216,104	$34,791,855	$10,039,809
Common Stock Issuance	$234,805,498	$65,216,104	$34,791,855	$10,039,809
Other
Repayment Of Debt	$-6,801,638	$-5,677,889	$-4,659,918	$-2,010,919
Issuance Of Debt	$0	$28,339,399	$0	$34,359,644
End Cash Position	$112,957,230	$109,831,662	$30,616,469	$98,653,318
Beginning Cash Position	$109,831,662	$30,616,469	$98,653,318	$98,445,174
Effect Of Exchange Rate Changes	$-532,302	$1,406,961	$506,142	$-1,165,833
Changes In Cash	$3,657,871	$77,808,232	$-68,542,992	$1,373,976
Interest Paid Cff	$-282,075	$0	$0	-
Proceeds From Stock Option Exercised	$66,203,365	$66,235,212	$0	$0
Net Issuance Payments Of Debt	$-6,801,638	$22,661,510	$-4,659,918	$32,348,725
Net Long Term Debt Issuance	$-6,801,638	$22,661,510	$-4,659,918	$32,348,725
Long Term Debt Payments	$-6,801,638	$-5,677,889	$-4,659,918	$-2,010,919
Long Term Debt Issuance	$0	$28,339,399	$0	$34,359,644
Net Investment Purchase And Sale	$-151,203,362	$10,325,295	$-8,328,025	$10,676,751
Purchase Of Investment	$-151,203,362	-	$-9,440,400	$-1,137
Net PPE Purchase And Sale	$-280,937	$-378,753	$-465,196	$-591,447
Sale Of PPE	$0	$0	$148,999	$46,633
Purchase Of PPE	$-280,937	$-378,753	$-614,195	$-638,080
Taxes Refund Paid	$5,590,309	$6,065,741	$5,937,215	$4,041,174
Change In Working Capital	$2,008,644	$1,909,691	$19,684,940	$6,497,952
Change In Other Working Capital	$-1,865,332	$2,040,491	$3,628,298	$-1,916,515
Change In Payables And Accrued Expense	$2,907,188	$-3,796,633	$22,750,227	$4,020,701
Change In Payable	$2,907,188	$-3,796,633	$22,750,227	$4,020,701
Change In Inventory	$0	$474,295	$-50,045	$21,611
Change In Receivables	$966,788	$3,191,538	$-6,643,539	$4,372,156
Other Non Cash Items	$242,428,337	$99,877,158	$2,440,855	$1,230,664
Stock Based Compensation	$30,446,996	$4,071,883	$4,514,331	$2,522,748
Deferred Tax	$-2,613,740	$-5,459,508	$-5,392,402	$-5,983,849
Deferred Income Tax	$-2,613,740	$-5,459,508	$-5,392,402	$-5,983,849
Depreciation Amortization Depletion	$3,665,832	$5,912,193	$2,956,096	$1,931,301
Depreciation And Amortization	$3,665,832	$5,912,193	$2,956,096	$1,931,301
Depreciation	$3,665,832	$5,912,193	$2,956,096	$1,931,301
Earnings Losses From Equity Investments	$398,089	$172,884	$2,291,856	$0
Net Foreign Currency Exchange Gain Loss	$1,549,136	$-1,280,710	$337,807	$390,127
Gain Loss On Sale Of PPE	$27,298	$518,653	$0	$0
Net Income From Continuing Operations	$-402,795,711	$-209,522,287	$-125,598,267	$-61,731,117
Sale Of Investment	-	$10,325,295	$1,112,375	$10,677,889

Fetched: 2026-06-25